AVROBIO(AVRO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights • TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 • Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024 • Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 million • Cash and cash equivalents were $185.1 million as of Ju ...